Roberto A. Calle

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 477 citations · Full text

Obesity, Metabolic Syndrome, Long-acting Fgf21 Molecule +12

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 207 citations

Obesity, Metabolic Syndrome, Dgat2 Inhibitor +12

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

Danna M. Breen, Hanna Kim, Donald Bennett et al. · Cell Metabolism · 2020 · 168 citations

Oncology, Weight Loss, Chemoprevention Strategy +10

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 136 citations

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

Harshal Deshmukh, Helen M. Colhoun, Toby Johnson et al. · Journal of Lipid Research · 2012 · 124 citations · Full text